Skip to content

Nasdaq · CIK 0001657677

PBLS Parabilis Medicines, Inc.

Insider trading from SEC Form 4. Last filing Aug 25, 2026. Close $26.85 on Oct 13, 2026, +7% from the 52-week low and -36% from the high.

In brief

Parabilis Medicines, Inc. (PBLS) has 17 SEC Form 4 filings on file from 11 insiders, the latest filed on Aug 25, 2026. In the last 90 days insiders made 1 open-market buy worth $6.9M and 0 open-market sells worth $0, net +$6.9M.

5 open-market trades have been scored at PBLS. The newest: Ra Capital Management, L.p. (director and 10% owner) bought $6.9M of stock on Jul 20, 2026, filed Jul 22, 2026, scored 35 (weak). The largest of the 5 shown: Ra Capital Management, L.p. (director and 10% owner) bought $424M on Jun 11, 2026, scored 60 (notable). 3 insiders bought within 14 days of each other around Jun 11, 2026.

Last 90 days

Net insider value
+$6.9M
more bought than sold
Buys
1
$6.9M by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company

Price and insider trades, last year

PBLSOct 13, 2026 · close 26.85

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Parabilis Medicines, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
35WeakRa Capital Management, L.p.
director, owner
buy
$6.9M
244,593 shares
+1%-
57ModerateGuy Levy
owner
buy
$10M
500,000 shares
+77%-
62NotableAlan Sebulsky
director
buy
$474k
17,500 shares
+140%-
60NotableRa Capital Management, L.p.
director, owner
buy
$424M
21,188,750 shares
+323%-
51ModerateAlan Sebulsky
director
buy
$250k
12,500 shares
--

Transactions

The newest 50 of 55 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Aug 22, 2026Craig Tendler
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,294$0.00$020,294Aug 25, 2026
Jul 20, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+98,433$27.13$2.7M26,383,526Jul 22, 2026
Jul 20, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+32,987$27.72$914k26,416,513Jul 22, 2026
Jul 21, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+21,696$27.96$607k26,438,209Jul 22, 2026
Jul 21, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+6,504$29.17$190k26,444,713Jul 22, 2026
Jul 21, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+37,723$30.00$1.1M26,482,436Jul 22, 2026
Jul 22, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+47,250$29.77$1.4M26,529,686Jul 22, 2026
Jun 11, 2026Guy Levy
owner
POpen-market purchase
Common Stock, par value $0.0001 per shareindirect: See footnote
+375,000$20.00$7.5M1,027,000Jun 29, 2026
Jun 11, 2026Guy Levy
owner
POpen-market purchase
Common Stock, par value $0.0001 per shareindirect: See footnote
+125,000$20.00$2.5M652,000Jun 29, 2026
Jun 11, 2026Guy Levy
owner
CConversion
Common Stock, par value $0.0001 per shareindirect: See footnote
+527,070$9.48$5.0M527,070Jun 29, 2026
Jun 11, 2026Guy Levy
owner
CConversion
Series F Preferred Stockderivativeindirect: See footnote
-527,070$0.00$00Jun 29, 2026
Jun 12, 2026Alan Sebulsky
director
POpen-market purchase
Common Stockindirect: By Apothecary Capital LLC
+8,435$27.67$233k20,935Jun 16, 2026
Jun 15, 2026Alan Sebulsky
director
POpen-market purchase
Common Stockindirect: By Apothecary Capital LLC
+5,000$26.00$130k25,935Jun 16, 2026
Jun 15, 2026Alan Sebulsky
director
POpen-market purchase
Common Stockindirect: By Apothecary Capital LLC
+4,065$27.10$110k30,000Jun 16, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Voting Common Stockindirect: See footnotes
+6,556,740--6,556,740Jun 15, 2026
Jun 11, 2026Alexis Borisy
director
CConversion
Common Stock
+105,414--105,414Jun 15, 2026
Jun 11, 2026Alan Sebulsky
director
POpen-market purchase
Common Stockindirect: By Apothecary Capital LLC
+12,500$20.00$250k12,500Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Common Stock
+5,539--5,539Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Voting Common Stockindirect: See footnotes
+1,187,881--1,187,881Jun 15, 2026
Jun 11, 2026Alexis Borisy
director
CConversion
Series F Preferred Stockderivative
+162,221--0Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Common Stock
+3,878--9,417Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+19,728,353$20.00$395M26,285,093Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Common Stock
+5,271--14,688Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Series B Preferred Stockderivative
+5,332--0Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
POpen-market purchase
Voting Common Stockindirect: See footnotes
+1,460,397$20.00$29M2,648,278Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Series C Preferred Stockderivative
+3,666--0Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Series E Preferred Stockderivativeindirect: See footnotes
-642,250--0Jun 15, 2026
Jun 11, 2026Edward M Fitzgerald
director
CConversion
Series F Preferred Stockderivative
+8,111--0Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Series E Preferred Stockderivativeindirect: See footnotes
-160,562--0Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Series F Preferred Stockderivativeindirect: See footnotes
-9,445,363--0Jun 15, 2026
Jun 11, 2026Ra Capital Management, L.p.
director, owner
CConversion
Series F Preferred Stockderivativeindirect: See footnotes
-1,666,829--0Jun 15, 2026
Jun 9, 2026Alexis Borisy
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Barbara Weber
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Krishna Yeshwant
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Edward M Fitzgerald
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Ra Capital Management, L.p.
director
AGrant or award
Stock Option (Right to Buy)derivativeindirect: See footnotes
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Richard Klausner
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 9, 2026Alan Sebulsky
director
AGrant or award
Stock Option (Right to Buy)derivative
+39,792$0.00$039,792Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Private Design Fund III, L.P.
+122,990--122,990Jun 11, 2026
Jun 9, 2026Jake Simson
director
AGrant or award
Stock Option (Right to Buy)derivative
+20,215$0.00$020,215Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P.
+122,990--122,990Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Private Design Fund III, L.P.
+149,238--272,228Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P.
+149,238--272,228Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Private Design Fund III, L.P.
+260,992--533,220Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P.
+260,992--533,220Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Private Design Fund III, L.P.
+407,132--940,352Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Voting Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P.
+407,132--940,352Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Series A Preferred Stockderivativeindirect: Through Deerfield Private Design Fund III, L.P.
-166,070--0Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Series A Preferred Stockderivativeindirect: Through Deerfield Healthcare Innovations Fund, L.P.
-166,070--0Jun 11, 2026
Jun 11, 2026James E Flynn
owner, other
CConversion
Series B Preferred Stockderivativeindirect: Through Deerfield Private Design Fund III, L.P.
-143,650--0Jun 11, 2026
50 of 55 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about PBLS

Answered from the filings on this page, as of the latest one.

Are insiders buying PBLS?

As of Aug 25, 2026, SEC Form 4 filings show 1 open-market buy worth $6.9M by 1 insider and 0 open-market sells worth $0 by 0 insiders at Parabilis Medicines, Inc. in the last 90 days, net +$6.9M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.

Who was the last insider to trade PBLS on the open market?

Ra Capital Management, L.p. (director and 10% owner) bought $6.9M of PBLS on Jul 20, 2026 and filed the Form 4 on Jul 22, 2026. InsiderTell scored 35 (weak).

How many insiders file Form 4 at Parabilis Medicines, Inc.?

11 people have filed a Form 4 at Parabilis Medicines, Inc., among them Alexis Borisy (director and chair), Edward M Fitzgerald (director), James E Flynn (10% owner and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.